The End­points R&D 15: How many block­busters does $124B buy the biggest spenders in drug re­search? (Not enough)

2 months ago
Special
Pharma

New pa­per sheds fresh light on Tmu­ni­ty's high-pro­file CAR-T deaths

2 months ago
R&D
Cell/Gene Tx

The 20(+1) un­der 40: Your guide to the next gen­er­a­tion of biotech lead­ers

2 months ago
Special

Guest col­umn: What hap­pened with Es­pe­ri­on — and what de­fines suc­cess or fail­ure?

2 months ago
Biotech Voices

'Em­pa­thy and love were not shown’: The sto­ry be­hind Taysha’s lay­offs, one of dozens of biotechs suf­fer­ing this year’s bear mar­ket

2 months ago
Cell/Gene Tx
In Focus

Af­ter Covid-19 suc­cess, pa­tients with the world’s ‘most stig­ma­tized’ in­fec­tion push for their own Op­er­a­tion Warp Speed

2 months ago
In Focus

The good, the bad and lots of just plain old ug­ly: The Q1 num­bers are in

2 months ago

Chirps, chats and Club­hous­es: First-time biotech founders turn to so­cial me­dia for ad­vice, in­vestors and re­cruit­ment

2 months ago
Startups
In Focus

Ex­clu­sive: Fol­low­ing a se­vere set­back, Bridge­Bio brings out the bud­get axe to chop staff but keeps qui­et on the num­bers

2 months ago
Pharma

Sanofi R&D team ac­cel­er­ates block­buster de­vel­op­ment ef­forts — while cast­ing doubt on a heavy­weight ri­val’s plans

2 months ago
Bioregnum

In­side the race to make psy­che­delics 'main­stream med­i­ci­nes'

2 months ago
R&D
In Focus

An Al­tos Labs ri­val? Genen­tech throws its hat in­to buzzy 'cel­lu­lar re­ju­ve­na­tion' field

3 months ago
R&D

Ex­clu­sive: ARCH and GV are build­ing a large start­up fo­cused on mi­to­chon­dr­i­al dis­eases

3 months ago
Startups

So, just how much are those CRISPR patents ac­tu­al­ly worth?

3 months ago
Deals
Cell/Gene Tx

FDA+ roundup: As­ses­sor finds FDA's new biosim­i­lar re­view mod­el makes the process more pre­dictable

4 months ago
FDA+

Bio­phar­ma has hyped AI for years. But as the first tri­als get un­der­way, ex­perts try to man­age ex­pec­ta­tions

4 months ago
AI
In Focus

Am­gen qui­et­ly kills an obe­si­ty pro­gram, cast­ing bleak fu­ture for once-promis­ing tar­get

4 months ago
R&D
Discovery

The 2022 top 100 bio­phar­ma in­vestors: A look back on boom times

4 months ago
Financing
Deals

FDA+ roundup: Biden's sci­en­tif­ic lead­er­ship in ma­jor flux; Cures 2.0 and ARPA-H to be pack­aged to­geth­er

4 months ago
FDA+

Ex­clu­sive: ARCH-backed ex­er­cise-in-a-pill start­up qui­et­ly laid off half its staff, ‘ful­ly piv­ot­ed’ in Oc­to­ber

4 months ago
Startups

UP­DAT­ED: Months af­ter Tmu­ni­ty ground to a halt on clin­i­cal hold, cell ther­a­py pi­o­neer Oz Azam is jump­ing to a stealth start­up

4 months ago
People

Of course the mar­ket de­ba­cle will in­flu­ence M&A, deal­mak­ing. The pen­du­lum is swing­ing back to buy­ers

4 months ago
Bioregnum

FDA+ roundup: Janet Wood­cock de­fends her 'most' will get Covid com­ment, talks short­ages and gov­ern­ment trust

5 months ago
FDA+

A new can­cer im­munother­a­py brings cau­tious hope for a field long await­ing the next big break­through

5 months ago
R&D
In Focus
First page Previous page 12345 Next page Last page